Development of novel treatment options for patients with haemophilia

Hamostaseologie

Volumn 33, Issue SUPPL.1, 2013, Pages

  Ehrlich, H J ^a   Wong, W Y ^b   Ewenstein, B M ^b   Dockal, M ^a   Turecek, P L ^a   Gringeri, A ^a   Chehadeh, H ^a   Low Baselli A ^a   Scheiflinger, F ^a   Reininger, A J ^a  

^a BAXTER INNOVATIONS GMBH   (Austria)

^b NONE

Author keywords

Gene therapy; Haemophilia; Long Acting Factor VIII; Prophylaxis

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; PARVOVIRUS VECTOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

COMPARATIVE EFFECTIVENESS; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; VIRAL GENE THERAPY; VON WILLEBRAND DISEASE;

GENE THERAPY; HAEMOPHILIA; LONG-ACTING FACTOR VIII; PROPHYLAXIS;

ADAM PROTEINS; ANTIBODIES, MONOCLONAL; BLOOD COAGULATION FACTORS; DRUG DESIGN; GENETIC THERAPY; HEMOPHILIA A; HUMANS; RECOMBINANT PROTEINS;

EID: 84888412772     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1619792     Document Type: Review

References (16)

1. Anson DS, Austen DE, Brownlee GG. Expression of active human clotting factor IX from recombinant DNA clones in mammalian cells. Nature 1985; 315: 683-685.
2. Choo KH, Gould KG, Rees DJ, Brownlee GG. Molecular cloning of the gene for human anti-haemophilic factor IX. Nature 1982; 299: 178-180.
3. Gitschier J, Wood WI, Goralka TM et al. Characterization of the human factor VIII gene. Nature 1984; 312: 326-330.
4. Leissinger C, Gringeri A, Antmen B et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365: 1684-1692.
5. Nathwani AC, Tuddenham EG, Rangarajan S et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365: 2357-2365.
6. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years_ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
7. Pool JG, Gershgold EJ, Pappenhagen AR. Highpotency antihaemophilic factor concentrate prepared from cryoglobulin precipitate. Nature 1964; 18: 203-212.
8. Pool JG, Shannon AE. Production of high-potency concentrates of antihaemophilic globulin in a closed-bag system. N Engl J Med 1965; 273: 1443-1447.
9. Simioni P, Tormene D, Tognin G et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med 2009; 361: 1671-1675.
10. Stafford DW, Chang JL. Factor IX antihemophilic factor with increased clotting activity. US Patent 6531298 (issued 2003).
11. Teitel JM, Barnard D, Israels S et al. Home management of haemophilia. Haemophilia 2004; 10: 118-133
12. Toole JJ, Knopf JL, Wozney JM et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342-347.
13. Valentino LA. Mamonov V, Hellmann A et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10: 359-367.
14. Vehar GA, Keyt B, Eaton D et al. Structure of human factor VIII. Nature 1984; 312: 337-342.
15. hite GC 2nd, McMillan CW, Kingdon HS et al. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia. N Engl J Med 1989; 320: 166-170.
16. Wood WI, Capon DJ, Simonsen CC et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312: 330-337.